Does Lurbinectedin Cause Hair Loss?
Lurbinectedin (Zepzelca), used for small cell lung cancer, lists alopecia (hair loss) as a common side effect in clinical trials, affecting 20-35% of patients depending on dose and combination therapy.[1][2] It's typically mild to moderate and reversible after treatment ends, but not all patients experience it.
Can You Prevent Hair Loss on Lurbinectedin?
No proven preventive options exist specifically for lurbinectedin-induced alopecia. Standard chemotherapy hair loss prevention strategies—like scalp cooling (cold caps)—show limited or no evidence for this drug. Scalp cooling reduces hair loss in taxane-based regimens by 50% but fails in many non-taxane chemotherapies, including platinum doublets often paired with lurbinectedin.[3][4] Trials exclude it due to weak efficacy data for similar agents.
What Do Doctors Recommend Instead?
Oncologists focus on management over prevention:
- Gentle hair care: Use mild shampoos, avoid heat styling, and pat dry instead of rubbing.
- Scalp protection: Wear hats or scarves outdoors; apply fragrance-free moisturizers to prevent dryness.
- Nutritional support: Ensure adequate protein, biotin, and iron intake, though no direct link to lurbinectedin alopecia.[5]
Discuss minoxidil (topical) with your doctor post-onset—it may speed regrowth in some chemo patients, but evidence is anecdotal.[6]
How Does Hair Loss Compare to Other Chemo Drugs?
| Drug/Regimen | Alopecia Rate | Reversible? | Scalp Cooling Works? |
|--------------|---------------|-------------|----------------------|
| Lurbinectedin | 20-35% | Yes | Limited/no data |
| Docetaxel | 70-100% | Yes | Often (50% reduction) |
| Cisplatin + etoposide (SCLC standard) | 50-70% | Yes | Inconsistent |
Lurbinectedin's rate is lower than taxanes but similar to other SCLC treatments.[2][7]
When Does Hair Regrow After Stopping?
Regrowth starts 1-3 months post-treatment, reaching full density in 6-12 months. Factors like age, baseline hair health, and treatment duration affect speed.[1]
Should You Worry About Permanent Loss?
Rare—less than 1% of cases. Persistent thinning ties more to underlying cancer or age than the drug itself.[5]
Sources
[1]: Zepzelca Prescribing Information - fda.gov
[2]: Trigo et al., Lancet Oncol 2020 - thelancet.com
[3]: Rugo et al., JAMA 2017 (Paz-Ares trial on cooling) - jamanetwork.com
[4]: NACEC Guidelines - naccme.com
[5]: ASCO Chemo Hair Loss Guidelines - asco.org
[6]: Jimenez et al., Support Care Cancer 2021 - link.springer.com
[7]: FDA SCLC Approvals Summary - fda.gov